by Rhoda Wilson, Expose News:
DARPA has openly bragged on Twitter that Moderna’s mRNA vaccine technology, and by extension Moderna’s Covid vaccine, was a product of their ADEPT program.
Below, Spartacus takes a look at the paper trail that shows Moderna is just another front in the Biodefence Mafia.
The introduction of foreign nucleic acids – RNA or DNA – into the body to generate foreign proteins is, by definition, gene therapy, regardless of whether or not the subject’s own genes are changed by it.
Cationic lipids, like the lipid nanoparticles used in mRNA vaccines, are capable of transfecting basically any type of cell with instructions to make proteins. If the immune system catches a cell producing non-human proteins, some seriously bad things will happen to that cell.
TRUTH LIVES on at https://sgtreport.tv/
There has been a major push for the adoption of nucleic acid vaccine tech in prior years, largely hidden from the public eye. In order to begin tracing it out, one must simply perform date range searches for the years prior to 2020, for nucleic acid vaccines. The cheerleaders of this technology immediately reveal themselves. And they are all looking for technology that is easy, rapid, and cost-effective for development and manufacture.
Naturally, the military would be interested in this technology for quickly vaccinating large populations of people against bioweapons ahead of pandemic spread, because it offers the potential for rapid development and deployment of countermeasures in a wartime scenario with equally rapid-developed bioweapons being flung all over the place. This is where DARPA’s ADEPT comes in.
DARPA openly brag on Twitter that Moderna’s mRNA vaccine technology, and by extension Moderna’s Covid vaccine, was a product of ADEPT. As Stat News reported:
“A review of dozens of patent applications found [Moderna] received approximately $20 million from the federal government in grants several years ago and the funds “likely” led to the creation of its vaccine technology. This was used to develop vaccines to combat different viruses, such as Zika and, later, the virus that causes Covid-19.”
Corporate media, with few exceptions, are largely silent on this matter. The reason you have been kept in the dark is because you are the target of a globe-spanning military operation, with population reduction, mass surveillance, tyrannical control of people’s movements, and the destruction of human autonomy through implanted technology as its end goal.
Nucleic Acid Vaccines
A nucleic acid vaccine is a vaccine that uses gene delivery methods, such as lipid nanoparticles or viral vectors, to deliver some quantity of either DNA or RNA into a cell. The cell’s own machinery, in the form of RNA polymerases and ribosomes, uses these nucleic acids as instructions to synthesize proteins. In the case of a nucleic acid vaccine, the protein in question is usually one of the structural proteins of a virus, with the aim of generating an antibody response against that specific protein, but this isn’t the only type of product that nucleic acid transfection can produce. Gene transfection into cells can, in fact, make those cells produce any kind of protein, with the right instructions, including monoclonal antibodies, designer receptors, anything imaginable.
In the case of the Covid-19 vaccines, the media and the medical establishment tried getting around this by arguing that since the vaccines did not change the recipient’s DNA, that meant that they weren’t gene therapy. The introduction of foreign nucleic acids into the body to generate foreign proteins is, by definition, gene therapy, regardless of whether or not the subject’s own genes are changed by it. DNA and RNA are genetic material, and if the immune system catches a cell producing non-human proteins, some seriously bad things will happen to that cell.
Unlike a virus – which only binds to specific host factors expressed by specific cell lines and is endocytosed in those specific cells – cationic lipids, like the lipid nanoparticles (“LNPs”) used in mRNA vaccines, are capable of transfecting basically any type of cell with instructions to make proteins. LNPs were investigated for many years as a means of delivering Alzheimer’s drugs to the brain because they readily bypass the blood-brain barrier.
When the thing being delivered is a toxin, like SARS-CoV-2 Spike, however, there are serious consequences.
The current report presents the case of a 76-year-old man with Parkinson’s disease (PD) who died three weeks after receiving his third Covid-19 vaccination.
The patient was first vaccinated in May 2021 with the ChAdOx1 nCov-19 vector [AstraZeneca] vaccine, followed by two doses of the BNT162b2 mRNA [Pfizer-BioNTech] vaccine in July and December 2021.
The family of the deceased requested an autopsy due to ambiguous clinical signs before death. PD was confirmed by post-mortem examinations. Furthermore, signs of aspiration pneumonia and systemic arteriosclerosis were evident. However, histopathological analyses of the brain uncovered previously unsuspected findings, including acute vasculitis (predominantly lymphocytic) as well as multifocal necrotising encephalitis of unknown aetiology with pronounced inflammation including glial and lymphocytic reaction. In the heart, signs of chronic cardiomyopathy as well as mild acute lympho-histiocytic myocarditis and vasculitis were present.
Although there was no history of Covid-19 for this patient, immunohistochemistry for SARS-CoV-2 antigens (spike and nucleocapsid proteins) was performed. Surprisingly, only spike protein but no nucleocapsid protein could be detected within the foci of inflammation in both the brain and the heart, particularly in the endothelial cells of small blood vessels.
Since no nucleocapsid protein could be detected, the presence of spike protein must be ascribed to vaccination rather than to viral infection. The findings corroborate previous reports of encephalitis and myocarditis caused by gene-based Covid-19 vaccines. [emphasis our own]
There has been a major push for the adoption of nucleic acid vaccine tech in prior years, largely hidden from the public eye. In order to begin tracing it out, one must simply perform date range searches for the years prior to 2020, for nucleic acid vaccines. The cheerleaders of this technology immediately reveal themselves.
Easy, Rapid, Cost-Effective Development and Manufacture
Nature – mRNA vaccines — a new era in vaccinology:
mRNA vaccines represent a promising alternative to conventional vaccine approaches because of their high potency, capacity for rapid development and potential for low-cost manufacture and safe administration. However, their application has until recently been restricted by the instability and inefficient in vivo delivery of mRNA.
Recent technological advances have now largely overcome these issues, and multiple mRNA vaccine platforms against infectious diseases and several types of cancer have demonstrated encouraging results in both animal models and humans. This Review provides a detailed overview of mRNA vaccines and considers future directions and challenges in advancing this promising vaccine platform to widespread therapeutic use. [emphasis our own]
Frontiers – Advances in mRNA Vaccines for Infectious Diseases:
During the last two decades, there has been broad interest in RNA-based technologies for the development of prophylactic and therapeutic vaccines.
Preclinical and clinical trials have shown that mRNA vaccines provide a safe and long-lasting immune response in animal models and humans. In this review, we summarise current research progress on mRNA vaccines, which have the potential to be quick-manufactured and to become powerful tools against infectious disease and we highlight the bright future of their design and applications. [emphasis our own]
Self-amplifying RNA or RNA replicon is a form of nucleic acid-based vaccine derived from either positive-strand or negative-strand RNA viruses. The gene sequences encoding structural proteins in these RNA viruses are replaced by mRNA encoding antigens of interest as well as by RNA polymerase for replication and transcription. This kind of vaccine has been successfully assayed with many different antigens as vaccine candidates, and has been shown to be potent in several animal species, including mice, nonhuman primates, and humans.
A key challenge to realising the broad potential of self-amplifying vaccines is the need for safe and effective delivery methods. Ideally, an RNA nanocarrier should provide protection from blood nucleases and extended blood circulation, which ultimately would increase the possibility of reaching the target tissue.
The delivery system must then be internalised by the target cell and, upon receptor-mediated endocytosis, must be able to escape from the endosomal compartment into the cell cytoplasm, where the RNA machinery is located, while avoiding degradation by lysosomal enzymes. Further, delivery systems for systemic administration ought to be well tolerated upon administration. They should be safe, enabling the multi-administration treatment modalities required for improved clinical outcomes and, from a developmental point of view, production of large batches with reproducible specifications is also desirable.
In this review, the concept of self-amplifying RNA vaccines and the most promising lipid-based delivery systems are discussed. [emphasis our own]
Nature Gene Therapy – The promise of nucleic acid vaccines:
Establishing the effective use of ‘naked’ nucleic acids as vaccines would undoubtedly be one of the most important advances in the history of vaccinology.
While nucleic acids show much promise for use as vaccine vectors in experimental animals, not a single naked nucleic acid vector has been approved for use in humans. Indeed, data from human clinical trials is scant: nucleic acid vaccines have not been clearly demonstrated to have any convincing efficacy in the prevention or treatment of infectious disease or cancer.
Here we illustrate possible mechanisms underlying effective nucleic acid vaccination. We focus on progress that has been made in the improvement of their function. Additionally, we identify promising new strategies and try to forecast future developments that could lead to the real success of nucleic acid vaccines in the prevention and treatment of human disease.
New vaccine platforms are needed to address the time gap between pathogen emergence and vaccine licensure. RNA-based vaccines are an attractive candidate for this role: they are safe, are produced cell free, and can be rapidly generated in response to pathogen emergence.
Two RNA vaccine platforms are available: synthetic mRNA molecules encoding only the antigen of interest and self-amplifying RNA (sa-RNA). sa-RNA is virally derived and encodes both the antigen of interest and proteins enabling RNA vaccine replication. Both platforms have been shown to induce an immune response, but it is not clear which approach is optimal.
In the current studies, we compared synthetic mRNA and sa-RNA expressing influenza virus hemagglutinin. Both platforms were protective, but equivalent levels of protection were achieved using 1.25 μg sa-RNA compared to 80 μg mRNA (64-fold less material). Having determined that sa-RNA was more effective than mRNA, we tested hemagglutinin from three strains of influenza H1N1, H3N2 (X31), and B (Massachusetts) as sa-RNA vaccines, and all protected against challenge infection. When sa-RNA was combined in a trivalent formulation, it protected against sequential H1N1 and H3N2 challenges. From this we conclude that sa-RNA is a promising platform for vaccines against viral diseases. [emphasis our own]
Again and again, the same properties are touted; easy, rapid, cost-effective development and manufacture. Plug in a gene sequence for the targeted antigen and away you go.
Naturally, the military would be interested in this technology for quickly vaccinating large populations of people against bioweapons ahead of pandemic spread, because it offers the potential for rapid development and deployment of countermeasures in a wartime scenario with equally rapid-developed bioweapons being flung all over the place.
ADEPT: PROTECT
ADEPT is a Defence Advanced Research Projects Agency (“DARPA”) program that began in 2012. The acronym stands for Autonomous Diagnostics to Enable Prevention and Therapeutics. PROTECT is a sub-program of ADEPT, and it stands for Prophylactic Options to Environmental and Contagious Threats.
